SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Study: Some Cancer Clinical Trials Being Spun in a Positive Light at Meetings Despite Negative Results
A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.
April 17, 2020
 · 
2 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: April 17
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
April 17, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Vir Shares Findings from Phase 1/2 Trial for VIR-2218 in Hepatitis B Virus
Data from the ongoing Phase II trial, as well as results from the Phase I trial of VR-2218, was released during a live webcast presentation on Wednesday.
April 16, 2020
 · 
2 min read
 · 
Michelle Brugioni
Drug Development
Following Lab Test, Eagle Pharma Looks to Test MH Drug Ryanodex Against COVID-19
In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic.
April 16, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: April 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
April 16, 2020
 · 
8 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 15
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
April 15, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
April 14, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 13
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
April 13, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Courtesy of Sundry Photography/Getty Images
Drug Development
Early Data from Gilead’s Compassionate Use of Remdesivir for COVID-19 Looks Promising
The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug.
April 13, 2020
 · 
3 min read
 · 
Mark Terry
BioCapital
Clinical Catch-Up: April 6-10
It was a very busy week for clinical trial news. Here’s a look.
April 10, 2020
 · 
12 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
January 30, 2024
 · 
5 min read
Drug Development
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
January 29, 2024
 · 
2 min read
Drug Development
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
 · 
9 min read
Drug Development
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
January 29, 2024
 · 
4 min read
Drug Development
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
January 29, 2024
 · 
11 min read
Drug Development
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
January 29, 2024
 · 
13 min read
Drug Development
Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery
January 28, 2024
 · 
4 min read
Drug Development
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
January 26, 2024
 · 
3 min read
Drug Development
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
January 25, 2024
 · 
8 min read
Drug Development
NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
January 25, 2024
 · 
3 min read
Drug Development
First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers
January 25, 2024
 · 
4 min read
Business
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
January 25, 2024
 · 
7 min read
Drug Development
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
January 25, 2024
 · 
6 min read
Drug Development
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
January 25, 2024
 · 
11 min read
Drug Development
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
January 24, 2024
 · 
2 min read
Drug Development
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
January 24, 2024
 · 
12 min read
Drug Development
Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
January 24, 2024
 · 
3 min read
Drug Development
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
January 24, 2024
 · 
3 min read
Drug Development
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
January 24, 2024
 · 
5 min read
Drug Development
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024
 · 
2 min read
Load More